Harrow (HROW) Non-Current Assets (2010 - 2026)
Harrow's (HROW) quarterly Non-Current Assets came in at $193.2 million in Q1 2026, down 0.76% year-on-year from $194.6 million in Q1 2025, and up 2.89% quarter-over-quarter from $187.7 million in Q4 2025.
Harrow (HROW) Non-Current Assets (2010 - 2026) Analysis & Trends
Harrow's Non-Current Assets history runs 16 years deep, the most recent figure standing at $193.2 million for Q1 2026.
- On a quarterly basis, Non-Current Assets fell 0.76% year-over-year to $193.2 million in Q1 2026; TTM through Mar 2026 was $756.5 million, a 1.2% decrease from a year earlier, with the FY2025 full-year figure at $187.7 million, down 5.81% from the prior year.
- Non-Current Assets improved to $193.2 million in Q1 2026 per HROW's latest filing, from $187.7 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $204.5 million in Q3 2024 and bottomed at $107000.0 in Q4 2022.
- The 5-year median for Non-Current Assets is $170.1 million (2024), against an average of $110.0 million.
- Across the five-year window, Non-Current Assets plunged 74.03% in 2022 and soared 161285.05% in 2023, its largest moves.
- Year by year, Non-Current Assets stood at $107000.0 in 2022, then surged by 161285.05% to $172.7 million in 2023, then advanced by 15.43% to $199.3 million in 2024, then fell by 5.81% to $187.7 million in 2025, then increased by 2.89% to $193.2 million in 2026.
- Per Business Quant, the three latest HROW Non-Current Assets figures stand at $193.2 million (Q1 2026), $187.7 million (Q4 2025), and $185.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | 193.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 193.16 Mn |
| Dec 31, 2025 | 187.73 Mn |
| Sep 30, 2025 | 185.47 Mn |
| Jun 30, 2025 | 190.14 Mn |
| Mar 31, 2025 | 194.63 Mn |
| Dec 31, 2024 | 199.32 Mn |
| Sep 30, 2024 | 204.48 Mn |
| Jun 30, 2024 | 167.24 Mn |
| Mar 31, 2024 | 170.08 Mn |
| Dec 31, 2023 | 172.68 Mn |
| Sep 30, 2023 | 780,000.00 |
| Jun 30, 2023 | 808,000.00 |
| Mar 31, 2023 | 902,000.00 |
| Dec 31, 2022 | 107,000.00 |
| Sep 30, 2022 | 994,000.00 |
| Jun 30, 2022 | 661,000.00 |
| Mar 31, 2022 | 411,000.00 |
| Dec 31, 2021 | 412,000.00 |
| Sep 30, 2021 | 36,000.00 |
| Jun 30, 2021 | 98,000.00 |